Helsinn Healthcare News and Activities
Executives
View the org chart displaying its 15 main executives
Most searched biographies at Helsinn Healthcare
- Riccardo Braglia, Chief Executive Officer
- Paolo Bottini, Board Member
- Riccardo Carbucicchio, Executive Chairman of the Board
Popular executive movements at Helsinn Healthcare
- Melanie Rolli, Group Chief Executive Officer, has left the company (posted on January 13 2026).
- Gabriele Braglia, who was Director, is promoted to Chief Business Officer and Deputy Chief Executive Officer (posted on January 13 2026).
- Riccardo Braglia, who was Board Member, is promoted to Chief Executive Officer (posted on January 13 2026).
Create your alert
to follow the executive moves at Helsinn Healthcare.
Pharmaceuticals
Helsinn Healthcare has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Corden Pharma has announced the acquisition of AmbioPharm (posted on June 5 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Helsinn Healthcare
- News - Helsinn
- News and Events - Helsinn
- https://www.helsinn.com/news-and-events/taiho-pharmaceutical-submits-new-drug-application-for-nk1-receptor-antagonist-fosnetupitant-for-prevention-of-gastrointestinal-symptoms-nausea-and-vomiting-associated-with-cancer-chemotherapy/
- https://www.helsinn.com/news-and-events/helsinn-publishes-prove-mf-ctcl-study-providing-new-data-for-mechlorethamine-gel-use-in-a-real-world-setting/
- Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
- https://www.helsinn.com/news-and-events/announcement-of-approval-to-manufacture-and-market-5-ht3-serotonin-receptor-antagonist-antiemetic-agent-palonosetron-i-v-injection-palonosetron-i-v-infusion-bag-in-japan/
- ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
- An interview with Dr. Larisa Geskin on an MF-CTCL fellowship at Columbia University supported by Helsinn
- Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
- https://www.helsinn.com/news-and-events/helsinn-demonstrates-commitment-to-raising-awareness-on-cachexia-by-supporting-cachexia-societies-conferences/
- View more press releases Close
Social media about Helsinn Healthcare
- Helsinn Healthcare on Wikipedia, Google News & Yahoo Finance
- Helsinn Healthcare on LinkedIn, X (Twitter) & YouTube
